´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â¿¡´Â ¿¬Æò±Õ 6.8%ÀÇ ¼ºÀå·ü·Î 142¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¿¹»óµÇ´Â ¼ºÀåÀº ¼¼±Õ °¨¿° Áõ°¡, Àα¸ °í·ÉÈ, ¼ºÇàÀ§ Áõ°¡, ¿ä·Î °¨¿° Áõ°¡, ÇÇÀÓ¾à »ç¿ë Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¿ø°ÝÀÇ·áÀÇ °³¹ß, ¿ø°ÝÀÇ·á ¼Ö·ç¼ÇÀÇ ÁÖ¿ä ¹ßÀü, ½Å¾àÀÇ Ã¢Ãâ, ¿ä·Î °¨¿° Ä¡·áÁ¦ÀÇ ¹ßÀü, ¿¬±¸°³¹ßÀÇ Áö¼ÓÀûÀÎ ÁøÀü µîÀÌ ÀÖ½À´Ï´Ù.
¸¸¼º ½ÅÀ庴(CKD)ÀÇ À¯º´·ü Áõ°¡´Â ´Ü¼ø ¿ä·Î°¨¿°(UTI) ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¸¸¼º ½ÅÀ庴(CKD)Àº ½ÅÀåÀÌ Á¡Â÷ ±â´ÉÀ» ÀÒ¾î ü³»¿¡ ³ëÆó¹°°ú ü¾×ÀÌ ÃàÀûµÇ´Â Àå±âÀûÀÎ ÁúȯÀ¸·Î, CKD ȯÀÚÀÇ Áõ°¡´Â ´ç´¢º´ À¯º´·ü Áõ°¡°¡ ÁÖ¿ä ¿øÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Àå±â°£ÀÇ °íÇ÷´çÁõÀº ½ÅÀå¿¡ ¼Õ»óÀ» ÀÔÇô ³ëÆó¹°À» Á¦´ë·Î °É·¯³»´Â ´É·ÂÀ» ¼Õ»ó½Ã۰í, CKD´Â ¸é¿ª ü°è¸¦ ¾àȽÃÄÑ ¿ä·Î °¨¿°¿¡ °É¸®±â ½±½À´Ï´Ù. ¶ÇÇÑ, ½ÅÀå ±â´ÉÀÌ ÀúÇÏµÇ¸é ¼Òº¯ÀÌ Á¤Ã¼µÇ±â ½¬¿ö ¼¼±ÕÀÌ ¹ø½ÄÇϱâ ÁÁÀº ȯ°æÀÌ µË´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 6¿ù Kidney Research UK´Â ¿µ±¹¿¡¼ ¸¸¼º ½ÅÀå ÁúȯÀ¸·Î ÀÎÇÑ ½ÅÀå À̽ÄÀÌ Áõ°¡ÇÏ¿© 2021³â 2,863°Ç¿¡¼ 2023³â 2,976°ÇÀ¸·Î Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. µû¶ó¼ ¸¸¼º ½ÅÀå ÁúȯÀÇ ºñÀ² Áõ°¡´Â ÇÕº´Áõ ¾ø´Â ¿ä·Î °¨¿° ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
´ç´¢º´ À¯º´·üÀÇ Áõ°¡´Â ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ç´¢º´Àº Àν¶¸° ºÐºñ ºÎÁ·À̳ª Àν¶¸° ÀÌ¿ë ºÎÁ·À¸·Î ÀÎÇÑ °íÇ÷´çÀ» Ư¡À¸·Î ÇÏ´Â ¸¸¼º ´ë»ç ÁúȯÀÔ´Ï´Ù. ´ç´¢º´ ȯÀÚÀÇ Áõ°¡´Â ½Ä½À°ü ¹× ¿îµ¿ ºÎÁ·°ú °°Àº °Ç°¿¡ ÇØ·Î¿î »ýȰ½À°ü¿¡ ±âÀÎÇÏ´Â ¹Ù°¡ Å®´Ï´Ù. °¡°ø½Äǰ°ú ´çºÐÀÌ ¸¹Àº ½ÄǰÀÇ ¼·Ãë Áõ°¡¿Í ¾É¾Æ¼ »ýȰÇÏ´Â ½À°üÀÌ Á¦2Çü ´ç´¢º´ÀÇ ÁÖ¿ä À§Çè¿äÀÎÀÎ ºñ¸¸À²ÀÇ Áõ°¡¸¦ ÃÊ·¡Çϰí ÀÖ½À´Ï´Ù. Ç÷´ç »ó½ÂÀº ¿ä·Î ¼¼±Õ Áõ½ÄÀ» ÃËÁøÇÏ°í ¿ä·Î °á¼® ¹ß»ý·üÀ» ³ôÀÔ´Ï´Ù. ¶ÇÇÑ ´ç´¢º´Àº ¸é¿ª ü°è¸¦ ¾àȽÃÄÑ ¿ä·Î °á¼®À» Æ÷ÇÔÇÑ °¨¿°¿¡ ´ëÇ×ÇÏ´Â °ÍÀ» ´õ ¾î·Æ°Ô ¸¸µì´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 3¿ù OHID(Office for Health Improvement &Disparities)´Â ¿µ±¹¿¡¼ 1Çü ´ç´¢º´ ȯÀÚ°¡ ÇÊ¿äÇÑ 8°¡Áö Ä¡·á °úÁ¤À» ¸ðµÎ ¹ÞÀº ºñÀ²Àº 1³â ¸¸¿¡ 35.2%¿¡¼ 43.8%·Î Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ¿¡ µû¶ó ´ç´¢º´ ȯÀÚÀÇ Áõ°¡´Â ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå Æ¯Â¡
Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«
Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À
Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©
- ¼¼°è ´Ü¼ø ¿ä·Î°¨¿° PESTEL ºÐ¼®(Á¤Ä¡, »çȸ, ±â¼ú, ȯ°æ, ¹ýÀû ¿äÀÎ, ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ)
- ÃÖÁ¾ ÀÌ¿ë »ê¾÷ ºÐ¼®
- ¼¼°èÀÇ ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå : ¼ºÀå·ü ºÐ¼®
- ¼¼°èÀÇ ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå ½ÇÀû : ±Ô¸ð¿Í ¼ºÀå, 2019-2024
- ¼¼°èÀÇ ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå ¿¹Ãø : ±Ô¸ð¿Í ¼ºÀå, 2024-2029, 2034F
- ¼¼°è ´Ü¼ø ¿ä·Î°¨¿° Àüü ½ÃÀå(TAM)
Á¦6Àå ½ÃÀå ¼¼ºÐÈ
- ¼¼°èÀÇ ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå Å×½ºÆ® Á¾·ùº°, ½ÇÀû°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
- ¼Òº¯ °Ë»ç
- ´¢¹è¾ç °Ë»ç
- °¨¼ö¼º ½ÃÇè
- ¼¼°èÀÇ ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå ¾à¹°¿¡ ÀÇÇÑ ½ÇÀû°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
- Æä´Ï½Ç¸°°ú ±× Á¶ÇÕ
- Äû³î·Ð
- ¼¼ÆÈ·Î½ºÆ÷¸°
- ¾ÆÁ¹°ú ¾ÏÆ÷Å׸®½Å B
- ´ÏÆ®·ÎÇ»¶õ
- ±âŸ ¾à¹°
- ¼¼°èÀÇ ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, ½ÇÀû°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
- º´¿ø
- Áø´Ü ½ÇÇè½Ç
- Á¶»ç±â°ü
- ¼¼°èÀÇ ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå ¼Òº¯ °Ë»ç Á¾·ùº° ÇÏÀ§ ¼¼ºÐÈ, ½ÇÀû°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
- µö½ºÆ½ Å×½ºÆ®
- Çö¹Ì°æ °Ë»ç
- ÀÚµ¿ ¼Òº¯ °Ë»ç
- ¼¼°èÀÇ ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå´¢¹è¾ç Á¾·ùº° ÇÏÀ§ ¼¼ºÐÈ, ½ÇÀû°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
- ÇÑõ ¹èÁö ¹è¾ç
- ºê·Î½º ¹è¾ç
- ¹ß»ö ¹èÁö
- ¼¼°èÀÇ ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå °¨¼ö¼º ½ÃÇè Á¾·ùº° ÇÏÀ§ ¼¼ºÐÈ, ½ÇÀû°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
- µð½ºÅ© È®»ê¹ý
- ÀÚµ¿ °¨¼ö¼º ½ÃÇè
- ºÐÀÚ °¨¼ö¼º ½ÃÇè
Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®
- ¼¼°èÀÇ ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå : Áö¿ªº°, ½ÇÀû°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
- ¼¼°èÀÇ ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå : ±¹°¡º°, ½ÇÀû°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå
Á¦9Àå Áß±¹ ½ÃÀå
Á¦10Àå Àεµ ½ÃÀå
Á¦11Àå ÀϺ» ½ÃÀå
Á¦12Àå È£ÁÖ ½ÃÀå
Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå
Á¦14Àå Çѱ¹ ½ÃÀå
Á¦15Àå ¼À¯·´ ½ÃÀå
Á¦16Àå ¿µ±¹ ½ÃÀå
Á¦17Àå µ¶ÀÏ ½ÃÀå
Á¦18Àå ÇÁ¶û½º ½ÃÀå
Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå
Á¦20Àå ½ºÆäÀÎ ½ÃÀå
Á¦21Àå µ¿À¯·´ ½ÃÀå
Á¦22Àå ·¯½Ã¾Æ ½ÃÀå
Á¦23Àå ºÏ¹Ì ½ÃÀå
Á¦24Àå ¹Ì±¹ ½ÃÀå
Á¦25Àå ij³ª´Ù ½ÃÀå
Á¦26Àå ³²¹Ì ½ÃÀå
Á¦27Àå ºê¶óÁú ½ÃÀå
Á¦28Àå Áßµ¿ ½ÃÀå
Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå
Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä
- ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå : °æÀï ±¸µµ
- ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå : ±â¾÷ °³¿ä
- Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- GSK plc Overview, Products and Services, Strategy and Financial Analysis
Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷
- Eli Lilly and Company
- Siemens AG
- Strykar Healthcare
- John Hopkins Medicine
- Shionogi & Co. Ltd.
- Sysmex Corporation
- Bio-Rad Laboratories Inc
- Cipla Inc.
- UTILITY therapeutics Ltd
- Orchid Pharma Limited
- ACON Labs
- Sonika Lifesciences
- Emergency Care BC
- EB Medicine
- Iterum Therapeutics PLC
Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå
Á¦33Àå ÁÖ¿ä ÀμöÇÕº´
Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ
Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«
- ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå 2029 : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ±¹°¡
- ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå 2029 : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ºÎ¹®
- ´Ü¼ø ¿ä·Î°¨¿° ½ÃÀå 2029 : ¼ºÀå Àü·«
- ½ÃÀå µ¿Çâ¿¡ ±â¹ÝÇÑ Àü·«
- °æÀï Àü·«
Á¦36Àå ºÎ·Ï
ksm
An uncomplicated urinary tract infection (UTI) is a bacterial infection of the bladder or urethra that typically occurs in healthy individuals without any structural issues or underlying health conditions. It most commonly affects the bladder (cystitis) and is caused by common uropathogens, such as Escherichia coli (E. coli). The primary goals of diagnosis and treatment are to relieve symptoms, prevent complications, and eradicate the infection using short-course antibiotics, ensuring a quick recovery without long-term effects.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main diagnostic tests in the uncomplicated urinary tract infection market include urinalysis, urine cultures, and susceptibility testing. Urinalysis is a laboratory test that analyzes a urine sample to detect and measure various substances, such as proteins, glucose, red and white blood cells, and bacteria. The market also includes a range of drugs, such as penicillin and its combinations, quinolones, cephalosporins, azoles and amphotericin B, nitrofurans, and others, along with various end-users such as hospitals, diagnostic labs, and research institutes.
The uncomplicated urinary tract infection market research report is one of a series of new reports from The Business Research Company that provides uncomplicated urinary tract infection market statistics, including uncomplicated urinary tract infection industry global market size, regional shares, competitors with an uncomplicated urinary tract infection market share, detailed uncomplicated urinary tract infection market segments, market trends and opportunities, and any further data you may need to thrive in the uncomplicated urinary tract infection industry. This uncomplicated urinary tract infection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The uncomplicated urinary tract infection market size has grown strongly in recent years. It will grow from $10.24 billion in 2024 to $10.98 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth observed during the historic period can be attributed to the increasing cases of renal failure, rising instances of bladder cancer, a higher prevalence of chronic kidney diseases, a growing use of urinary catheters, and the rising prevalence of diabetes.
The uncomplicated urinary tract infection market size is expected to see strong growth in the next few years. It will grow to $14.27 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth projected during the forecast period can be attributed to the rise in bacterial infections, an aging population, increased sexual activity, a growing number of urinary tract infections, and the rising use of contraceptives. Key trends during this period include the development of telemedicine, advancements in telehealth solutions, the creation of novel drugs, progress in urinary tract infection therapeutics, and continued advancements in research and development.
The growing prevalence of chronic kidney diseases (CKD) is expected to drive the expansion of the uncomplicated urinary tract infection (UTI) market. CKD is a long-term condition where the kidneys gradually lose their function, causing waste and fluid to build up in the body. The rise in CKD cases is largely attributed to the increasing prevalence of diabetes, as high blood sugar over time can damage the kidneys, impairing their ability to filter waste properly. CKD weakens the immune system, making individuals more vulnerable to urinary tract infections. Furthermore, poor kidney function can lead to urine retention, creating an environment conducive to bacterial growth. For example, in June 2023, Kidney Research UK reported an increase in kidney transplants in the UK due to chronic kidney disease, with the number rising from 2,863 transplants in 2021 to 2,976 in 2023. Therefore, the increasing rates of chronic kidney diseases are expected to fuel the growth of the uncomplicated urinary tract infection market.
The rising incidence of diabetes is expected to drive the growth of the uncomplicated urinary tract infection market. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels due to insufficient insulin production or poor insulin utilization. The rise in diabetes cases is largely due to unhealthy lifestyle habits, such as poor diet and lack of physical activity. The increased consumption of processed foods and sugary products, along with sedentary behavior, has contributed to higher obesity rates, a major risk factor for type 2 diabetes. Elevated blood sugar levels foster bacterial growth in the urinary tract, leading to a higher incidence of UTIs. Moreover, diabetes can compromise the immune system, making it more difficult for the body to combat infections, including UTIs. For instance, in March 2024, the Office for Health Improvement & Disparities (OHID) reported that in England, the percentage of individuals with Type 1 diabetes receiving all eight required care processes increased from 35.2% to 43.8% in just one year. Consequently, the rising cases of diabetes are expected to drive the growth of the uncomplicated urinary tract infection market.
Key companies in the uncomplicated urinary tract infection (UTI) market are focusing on developing new antibiotics to improve treatment effectiveness and address the challenge of antibiotic-resistant bacteria. Antibiotics work by killing or inhibiting the growth of bacteria in the body to treat infections. For example, in April 2024, the U.S. Food and Drug Administration (FDA) approved Pivya (pivmecillinam) tablets for the treatment of uncomplicated urinary tract infections in adult females. This tablet targets UTIs caused by susceptible strains of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. Pivmecillinam is a prodrug that converts into mecillinam, a beta-lactam antibiotic that works by disrupting the cell wall synthesis of gram-negative bacteria. These advancements in antibiotic development are strengthening the effectiveness of UTI treatments.
Major players in the uncomplicated urinary tract infection market are Cardinal Health, Pfizer Inc., Bayer AG, AstraZeneca plc, GSK plc, Eli Lilly and Company, Siemens AG, Strykar Healthcare, John Hopkins Medicine, Shionogi & Co. Ltd., Sysmex Corporation, Bio-Rad Laboratories Inc, Cipla Inc., UTILITY therapeutics Ltd, Orchid Pharma Limited, ACON Labs, Sonika Lifesciences, Emergency Care BC, EB Medicine, Iterum Therapeutics PLC.
North America was the largest region in the uncomplicated urinary tract infection market in 2024. The regions covered in uncomplicated urinary tract infection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the uncomplicated urinary tract infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The uncomplicated urinary tract infection market consists of sales of urinary analgesics, pH-altering agents, and hydration and supportive supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Uncomplicated Urinary Tract Infection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on uncomplicated urinary tract infection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for uncomplicated urinary tract infection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The uncomplicated urinary tract infection market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Test Type: Urinalysis; Urine Cultures; Susceptibility Testing
- 2) By Drug: Penicillin And Combinations; Quinolones; Cephalosporin; Azoles And Amphotericin B; Nitrofurans; Other Drugs
- 3) By End-Users: Hospitals; Diagnostic Labs; Research Institutes
- Subsegments:
- 1) By Urinalysis: Dipstick Tests; Microscopic Examination; Automated Urinalysis
- 2) By Urine Cultures: Agar Plate Culture; Broth Culture; Chromogenic Media
- 3) By Susceptibility Testing: Disk Diffusion Method; Automated Susceptibility Testing; Molecular Susceptibility Testing
- Companies Mentioned: Cardinal Health; Pfizer Inc.; Bayer AG; AstraZeneca plc; GSK plc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Uncomplicated Urinary Tract Infection Market Characteristics
3. Uncomplicated Urinary Tract Infection Market Trends And Strategies
4. Uncomplicated Urinary Tract Infection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Uncomplicated Urinary Tract Infection Growth Analysis And Strategic Analysis Framework
- 5.1. Global Uncomplicated Urinary Tract Infection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Uncomplicated Urinary Tract Infection Market Growth Rate Analysis
- 5.4. Global Uncomplicated Urinary Tract Infection Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Uncomplicated Urinary Tract Infection Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Uncomplicated Urinary Tract Infection Total Addressable Market (TAM)
6. Uncomplicated Urinary Tract Infection Market Segmentation
- 6.1. Global Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Urinalysis
- Urine Cultures
- Susceptibility Testing
- 6.2. Global Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Penicillin And Combinations
- Quinolones
- Cephalosporin
- Azoles And Amphotericin B
- Nitrofurans
- Other Drugs
- 6.3. Global Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Diagnostic Labs
- Research Institutes
- 6.4. Global Uncomplicated Urinary Tract Infection Market, Sub-Segmentation Of Urinalysis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Dipstick Tests
- Microscopic Examination
- Automated Urinalysis
- 6.5. Global Uncomplicated Urinary Tract Infection Market, Sub-Segmentation Of Urine Cultures, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Agar Plate Culture
- Broth Culture
- Chromogenic Media
- 6.6. Global Uncomplicated Urinary Tract Infection Market, Sub-Segmentation Of Susceptibility Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Disk Diffusion Method
- Automated Susceptibility Testing
- Molecular Susceptibility Testing
7. Uncomplicated Urinary Tract Infection Market Regional And Country Analysis
- 7.1. Global Uncomplicated Urinary Tract Infection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Uncomplicated Urinary Tract Infection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Uncomplicated Urinary Tract Infection Market
- 8.1. Asia-Pacific Uncomplicated Urinary Tract Infection Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Uncomplicated Urinary Tract Infection Market
- 9.1. China Uncomplicated Urinary Tract Infection Market Overview
- 9.2. China Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Uncomplicated Urinary Tract Infection Market
- 10.1. India Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Uncomplicated Urinary Tract Infection Market
- 11.1. Japan Uncomplicated Urinary Tract Infection Market Overview
- 11.2. Japan Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Uncomplicated Urinary Tract Infection Market
- 12.1. Australia Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Uncomplicated Urinary Tract Infection Market
- 13.1. Indonesia Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Uncomplicated Urinary Tract Infection Market
- 14.1. South Korea Uncomplicated Urinary Tract Infection Market Overview
- 14.2. South Korea Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Uncomplicated Urinary Tract Infection Market
- 15.1. Western Europe Uncomplicated Urinary Tract Infection Market Overview
- 15.2. Western Europe Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Uncomplicated Urinary Tract Infection Market
- 16.1. UK Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Uncomplicated Urinary Tract Infection Market
- 17.1. Germany Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Uncomplicated Urinary Tract Infection Market
- 18.1. France Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Uncomplicated Urinary Tract Infection Market
- 19.1. Italy Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Uncomplicated Urinary Tract Infection Market
- 20.1. Spain Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Uncomplicated Urinary Tract Infection Market
- 21.1. Eastern Europe Uncomplicated Urinary Tract Infection Market Overview
- 21.2. Eastern Europe Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Uncomplicated Urinary Tract Infection Market
- 22.1. Russia Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Uncomplicated Urinary Tract Infection Market
- 23.1. North America Uncomplicated Urinary Tract Infection Market Overview
- 23.2. North America Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Uncomplicated Urinary Tract Infection Market
- 24.1. USA Uncomplicated Urinary Tract Infection Market Overview
- 24.2. USA Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Uncomplicated Urinary Tract Infection Market
- 25.1. Canada Uncomplicated Urinary Tract Infection Market Overview
- 25.2. Canada Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Uncomplicated Urinary Tract Infection Market
- 26.1. South America Uncomplicated Urinary Tract Infection Market Overview
- 26.2. South America Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Uncomplicated Urinary Tract Infection Market
- 27.1. Brazil Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Uncomplicated Urinary Tract Infection Market
- 28.1. Middle East Uncomplicated Urinary Tract Infection Market Overview
- 28.2. Middle East Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Uncomplicated Urinary Tract Infection Market
- 29.1. Africa Uncomplicated Urinary Tract Infection Market Overview
- 29.2. Africa Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Uncomplicated Urinary Tract Infection Market Competitive Landscape And Company Profiles
- 30.1. Uncomplicated Urinary Tract Infection Market Competitive Landscape
- 30.2. Uncomplicated Urinary Tract Infection Market Company Profiles
- 30.2.1. Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis
31. Uncomplicated Urinary Tract Infection Market Other Major And Innovative Companies
- 31.1. Eli Lilly and Company
- 31.2. Siemens AG
- 31.3. Strykar Healthcare
- 31.4. John Hopkins Medicine
- 31.5. Shionogi & Co. Ltd.
- 31.6. Sysmex Corporation
- 31.7. Bio-Rad Laboratories Inc
- 31.8. Cipla Inc.
- 31.9. UTILITY therapeutics Ltd
- 31.10. Orchid Pharma Limited
- 31.11. ACON Labs
- 31.12. Sonika Lifesciences
- 31.13. Emergency Care BC
- 31.14. EB Medicine
- 31.15. Iterum Therapeutics PLC
32. Global Uncomplicated Urinary Tract Infection Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Uncomplicated Urinary Tract Infection Market
34. Recent Developments In The Uncomplicated Urinary Tract Infection Market
35. Uncomplicated Urinary Tract Infection Market High Potential Countries, Segments and Strategies
- 35.1 Uncomplicated Urinary Tract Infection Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Uncomplicated Urinary Tract Infection Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Uncomplicated Urinary Tract Infection Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
- 250617_r35002_Uncomplicated_Urinary_Tract_Infection_GMR_2025